Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is of fair value on EV/EBITDA.
Target Price
The average target price of VRAX is 1.00 and suggests 63.5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d